¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æרҵ£º GZt] 38V)g  
tK H!xit  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Y5CE#&  
||HIp9(3  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) pAuwSn#i  
mg(56)  
1. ICAM-1 kDh(~nfj  
W |e>  
2. interleukin 12(IL-12) 8|GpfW3p 2  
gi>_>zStv  
3. tumor infiltrating lymphocyte $H}Mn"G  
?g4|EV-56  
4. TCR/CD3 complex 9(WC#-,  
`qz5rPyZ  
5. hematopoietin receptor family GcCs} (eo  
Nk4_!  
6. individual idiotype(IdI)  !ei20@  
C>dJ:.K%H  
7. integrin AHY)#|/)  
8-ssiiJ}gh  
8. colony-stimulatory factor (CSF) qEr[fC@x  
MA# !<b('  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© Y{|yB  
`kSCH; mwP  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? J)|K/W9  
O Zm[i H  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ .G~5F- 8'  
TcmZ0L^O  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ4$GRCq5N;  
)ZyuF(C&  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØϵ¡£ ]mo<qWRc>p  
n12c075  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) FXEfD"  
g4SYG)'R+  
1. ÊÔÊö¸ÉÈÅËصķÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌص㡣Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËؼì²âµÄ·½·¨ºÍÔ­Àí¡£ {59VS Nl  
L9?/ -@M  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ä¿Ç°¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æרҵ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) Rn_W|"  
ff./DMDafI  
3. immunoglobulin superfamily (IgSF) h]DE Cd{  
D4]B>  
4. selectin FDs^S)B  
$RNUr \9A  
5. anti-idiotypic antibody (¦ÁId) UMi`u6#  
)u)$ `a  
6. major histocompatibility complex(MHC) v[DbhIXU  
qq7X ",s  
7. immunotolerance 4|41^B5Y  
bKMR7&e.Ep  
8. biological reponse modifier(BRM) _u|FJTk  
mS~ ]I$  
9. immune reponse gene (Ir gene) u#@{%kPW  
[gns8F#H\  
10. reshaped antibody (or reconstituted antibody) $#ju?B~  
V]kGcS}  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ,ibPSN5Ca  
x gT~b9  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ ;!JX-Jq  
oBNX8%5w  
2. ϸ°û¶¾ÐÔTÁÜ°Íϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? fxoi<!|iGY  
@-&( TRbZo  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ hN_f h J  
Q6!v3P/h  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? M|({ 4C  
g?[& 0r1  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ @6 ;oN  
r -q3+c^+  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? Ph#F<e(9  
pba8=Z  
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ Vl 19Md  
4OOn,09  
¹©Ïû»¯ÄÚ¿ÆרҵÊÔÌ⣺ bH\C5zt6(  
%`?;V;{=  
1. Ä¿Ç°ÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? "rx^M*"  
46K&$6eN  
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ ![@T iM  
2\nN4WL 5.  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æרҵ: 6mu<&m @  
6 tc:A5mK  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: 6hM]%  
!0ce kSesr  
ÃâÒßѧ BeI;#m0  
s s`P QN  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© ;Rhb@]X  
#`La|a.-  
1. CD8 zUs~V`0  
}qiF^D}  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) L\}Pzxn  
U !c]_q  
3. immunoglobulin fold(Ig fold) B f5 &}2u  
BrJ o!@<  
4. cadherin (Ca-dependent cell adhesion moleculers) L`UG=7r q  
P3iA(3I24<  
5. idiotype-anti-idiotypic antibody immune network theory gEv->pc  
WY+(]Wkao  
6. HLA class II antigen >[ug zJ  
xfq]9<  
7. complementarity-determining region (CDR) ch@x]@-;A3  
,0!uem}1i  
8. perforin(or pore-forming protein ,PFP) lDW!Fg  
D@8jGcz62  
9. high affinity IL-2 receptor 1GtOA3,~;-  
F =XF]  
10. artificial active immunization M@|w[ydQG  
S|"Fgoj r  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ZCm1+Y$  
ngP7'1I  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ*B0V< mV  
YgCc|W3{  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 o2DtCU-A  
[#p&D~Du&  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ jm[}M  
Qi_&aU$>lM  
4. ÊԱȽÏT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃ濹ԭ¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ osl=[pm  
D%-{q>F!gf  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐÑ¡Ò»Ìâ,3¡¢4ÌâÖÐÑ¡Ò»Ìâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ä¿Ç°¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ TfJL+a0  
wG+=}1X  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? 1t+%Gv^sK  
XdpF&B&K7Q  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ LZ{YmD&6]  
"Nbos.a]5  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ Gz ?2b#7v  
J{d(1gSZ  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ K"L_`.&Q  
>9=:sSQu  
ѧ¿Æרҵ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ ?w*yW;V`  
& 1[y"S  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© m4@MxQm  
3L>d!qD  
1. immunoglobulin gene rearrangement 3YW=||;|Yg  
,;%y f?  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) [EgW/\35  
GB>aT-G7q  
3. flow cytometry(FCM) lyyX <=E{)  
}p=g*Zo*C;  
4. carrier effect X8b|]Nr  
qgx?"$ Z  
5. positive selection of T lymphocytes in thymus %hc'dZ  
dAL3.%  
6. mouse TH1(Th1) and TH2(Th2) subsets wz#A1F  
b#/i.!:a  
7. perforin (pore-forming protein ,PFP) \0ov[T N.>  
A2NF<ZsD  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) JO=1ivZl  
+{$QAjW(/  
9. SH-2(src-homology region 2) ZYcd.?:6  
',{7% G9  
10. Ab2¦Â (internal image) pjw aL^  
_6MdF<Xb/  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© Gf0,RH+  
rwSbqL^eM  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? g?G+dnl/8  
$*\L4<(  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? >$H|:{D  
>o~Z>lr  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ\:v$ZEDJ>  
r &%.z*q  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ k1='c7s  
Puh$%;x  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ!%PWig-  
<G ~>~L.E  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) a{'Z5ail  
LA%bq_> f  
ÃâÒßѧרҵ£º  AIRr{Y  
.lNs4e  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ BqH]-'1G  
qAY%nA>jO  
2. ÊԱȽÏÈËT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? Jblj^n?Bm  
3y A2WW  
´«È¾²¡Ñ§×¨Òµ£º =IjQ40W  
[/ M`  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦ÄÜ¿É·¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ hs+kr?Pg`  
{9LWUCpsf  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØϵ¡£ IQH[Q9%  
7~1IO|4t  
Ïû»¯×¨Òµ£º o "z@&G" ^  
57,dw-|xi  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ n_u1&a'  
0N:XIGFa  
2.¼òÊöճĤÏà¹ØÁÜ°ÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌص㡣·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? '%saL>0  
 n_nl{  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ Q.U$nph\%d  
GV.A+u  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© w5=tlb  
3)=c]@N0  
1. Fas(CD95)/FasL @Xp~2@I=ls  
` `U^COD  
2. common chain of cytokine receptor !g!5_ |  
E:`v+S_h  
3 . TCR/CD3 complex Ro(Zmk\t  
U_GgCI)  
4. negaive selection of thymocytes KhbYr$  
DL'iS  
5. artificial active immune Ev"|FTI/  
Z4hrn::  
6. anti-idiotypic tCG76LH  
<S75($  
7. IgSF `Z"Q^  
\b=Pj!^gwb  
8. Integrin yS(}:'`r  
}Ew hj>w  
9. chemokine  gKz(=  
zq+o+o>xo  
10. B7/CD28 uj>WgU  
(Rt7%{*  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© mrIh0B:`  
7/7Z`  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ )a@k]#)Skm  
W&(k!6<x  
2. ±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌص㡣 >_OYhgs1w  
3 >E%e!D%  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ O$/o'"@ /  
o8 e?J\?  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆʵÑé·½°¸¿Ë¡´Ë»ùÒò¡£ oi}i\: hI  
7dsefNPb  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ ,p(<+6QZ  
3 rLTF\  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ s,#>m*Rh  
ljl^ GFo  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© z [`@}}Q  
;XM{o:1Y[  
1. B7/CD28 `Al;vVMRO  
AJ#Nenmj  
2. Th1 subset CLvX!O(~  
__mF ?m  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© jw-0M1B  
87hq{tTs]  
4. antibody affinity maturation McB[|PmC  
9tF9T\jW  
5. AP-1 %|s+jeUDn|  
>EY3/Go>  
6. single chain variable fragment£¨ScFv£© p]3?gK-  
Lemui)  
7. NK cell receptor p K0"%eA  
&b:1I 7Cp*  
8. Zinkernagel-Doherty phenomenon t!RiUZAo  
SdD6 ~LS  
9. Ig fold ):iA\A5q[  
m*JaXa  
10. CD40/CD40L eM8}X[  
dAuJXGo  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© `V##Y  
9T<x&  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØϵ¡£ eA<0$Gs,h  
#\ =FO>  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ !r<pmr3f@7  
@;"|@!l|  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹Øϵ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ 9H]{g*kL  
YOcO4   
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ 79;<_(Y  
PUUwv_  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁÜ°Íϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ 'dn]rV0(C  
kDsFR#w&`  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ #{;k{~;PF  
+~p88;  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æרҵ£©¡£ o2F)%TDY  
{z{bY\  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© .6Pw|xu`Pw  
,5h)x"s  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© DW[N|-L  
rbWP78  
1.Co-stimulators (or co-stimulating molecules) GB=X5<;  
vQ 6^xvk]  
2.NK-kB 4\iOeZR f  
;{N!Eb`S  
3.Immunoglobulin superfamily U2W|:~K M  
C&(N I  
4.antigen-presenting cell (APC) .[ICx  
.(cw>7e3D  
5.death domain I=`U7 Bis"  
)6Fok3u  
6.CCR and CXCR _ 9F9W{'  
&i6),{QN  
7.Lectin (or mitogen) ?67Y-\}   
)"7iJb<E  
8.Clusters of differentiation, CD) UM"- nZ>[  
inMA:x}cF1  
9.B7 family 'a@/vx&J  
k_rt&}e+Gi  
10.Cytotoxic T lymphocyte, CTL) B|C2lu  
Ng2twfSl$  
11.IL-15 and IL-15 receptor (IL-15R) L>Fa^jq5  
4V)kx[j  
12.MHC restriction KJ)k =mJ  
S%Uutj\/W  
13.Affinity-chromatography vXrx{5gz  
(c=6yV@  
14.Cyctosprin A, CsA z]_wjYn Z  
ZbW17@b  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) z!ZtzD]cb  
/NI;P]s.  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© Z&+ g;(g  
On9A U:\  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 P~>O S5^  
#wwH m3  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£ q376m-+  
O:;w3u7;u  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌص㡣 -P$PAg5"2  
NX*Q  F+  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© t&C1Oo}=3  
] vHF~|/-  
ÃâÒßѧרҵ£º P9^Xm6QO  
24 'J  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ xX&+WR  
n,y ZRY  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ i#n0U/  
U`(ee*}o  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ t%0VJB,Q2  
{L{o]Ii?g  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) =7=]{Cx[  
3wF;GG  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) LYTd TP  
Xx~Bp+  
1. ADCC(antibody dependent cell-mediated cytotoxicity) I3L<[-ZE  
gD @){Ip  
2. »·æß¾úËØ(cyclosporin) {UI+$/v#  
hED}h![  
3. KIR(killer cell inhibitory receptor) PO: { t  
03X1d-  
4. HLDA(human leucocyte differentiation antigen) Naf0)3q>!  
W:2( .?  
5. Interleukin 18(IL-18) 9s q  
s2V:cMXFn  
6. ÕûºÏËØ(integrin) K\Wkoi5  
'o2Fa_|<#  
7. Fas/FasL m+[Ux{$  
zR:L! S  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) <)H9V-5aZ  
'n3uu1C  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) Q(?#'<.#  
oLeq!K}re  
10. Th1/Th2 B~ GbF*j  
N =}A Z{$  
11. »ùÒòÒßÃç(DNAÒßÃç) X&`t{Id?6  
G9cUD[GB  
12. chemokines and chemokine receptor k="i;! G e  
KkbDW3-  
13. ÃâÒßÄÍÊÜ ^jZbo {  
FTUv IbT  
14. ¹²´Ì¼¤·Ö×Ó yR{3!{r3(  
+a+Om73B2  
15. ËÀÍö½á¹¹Óò(death domain) dUZ ,m9u  
z Rr*7G  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) aX'*pK/-  
K w ]=  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉË°Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? @# l=  l  
}19\.z&J  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»Æƶø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠon `3&0,.  
m;QMQeGz  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î E ~<J C"]  
'5$b-x6F  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ ukyZes8o K  
x s|FE3:a  
£¨3£©1984Ä꣺ÁÜ°Íϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå /a4{?? #e  
M .mfw#*  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄЩÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ EaN6^S=  
Gyc]?m   
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) yY q,*<G  
!+v$)3u9  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ 0@oJFJrO  
4,DeHJjAlE  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ C~/a-  
.?$gpM?i  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆһϵͳʵÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃÇ°¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÂÛ̳ÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»